Brief: Repare Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Rp-6306, A First-In-Class, Selective, Oral Inhibitor Of Pkmyt1
03/05/2021 13:15
May 3 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1
CLINICAL
TRIAL OF RP-6306, A FIRST-IN-CLASS, SELECTIVE, ORAL INHIBITOR OF
PKMYT1
Source text for Eikon: ID:nBw8Wpc7Ja
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln